An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controlled trial
© Federici et al.; licensee BioMed Central Ltd. 2012
Received: 4 April 2012
Accepted: 20 September 2012
Published: 25 September 2012
Xerosis is a common skin disorder frequently observed in diabetic patients. An effective hydration of foot skin in diabetics is a relevant preventive strategy in order to maintain a healthy foot. Urea is considered an effective hydrating and emollient topical product. The aim of the present study was to evaluate the efficacy of topical urea 5% with arginine and carnosine (Ureadin Rx Db, ISDIN Spain) (UC) in comparison with glycerol-based emollient topical product (Dexeryl, Pierre Fabre) (EC), in Type 2 diabetic patients.
We assessed the effect of UC on skin hydration in a randomized, evaluator-blinded comparative study in 40 type II diabetic patients, aged 40–75 years, treated with UC or the comparator for 28 days with a twice-daily application. The principal outcomes were the Dryness Area Severity Index (DASI) Score and the Visual Analogue Score (VAS) for skin dryness evaluated at baseline and at the end of study period by an investigator unaware of treatment allocation.
UC induced significantly greater hydration than EC with an 89% reduction in DASI score (from 1.6 to 0.2; p < 0.001) in comparison with baseline values. After 4 weeks, compared with the control group, DASI score in UC treated group was significantly lower (0.2 vs. 1.0; p = 0.048). VAS score (high values mean better hydration) significantly increased in both groups during treatment. VAS score at the end of treatment period was significantly higher in UC group in comparison with EC group (9.8 vs. 8.2; p = 0.05).
Application of urea 5%, arginine and carnosine cream increases skin hydration and alleviates the condition of skin dryness in Type 2 diabetic patients in comparison with a control glycerol-based emollient product. (Dutch Trials Register trial number 3328).
KeywordsSkin xerosis Diabetes Urea Controlled trial
Cutaneous complications are common in diabetes, with approximately 30% of patients experiencing some skin involvement during the course of their illness and these may also be an early indicator of undiagnosed diabetes. In particular xerosis is a common skin disorder frequently observed in diabetic patients. Skin xerosis and callous formation could be risk factors for diabetic ulcers developing. An effective hydration of foot skin in diabetics is a relevant preventive strategy in order to maintain a healthy foot. Emollient and moisturizer topical products are efficacious in repairing the epidermal barrier function and in ameliorating xerosis. However few studies have been conducted in diabetic patients assessing wheter this treatment can help correct alterations in functional and mechanical properties of diabetic skin. Urea is considered an effective hydrating and emollient topical product. Recent experimental data performed in human keratinocytes suggest that urea is not a simple emollient compound but it is able to improve cell differentiation increasing gene expression of transglutaminase, filaggrin, aquaporin, and loricrin, therefore improving keratinocytes differentiation. Arginine is an important substrate for Nitric Oxide formation. In diabetic skin a deficit in NO production has been demonstrated. This reduction could be due to an enhanced arginine consumption linked to high arginase enzymatic activity. Carnosine is able to interfere with advanced glycosylated end-products formation. This action has been also demonstrated for urea. Recently a topical cream product containing urea 5%, arginine and carnosine has been developed (Ureadin Rx Db, Isdin Spain). This formulation, from a theoretical point of view, is an interesting topical product with a composition particularly suitable for the specific treatment of the xerotic skin in diabetic patients. However, so far, not controlled clinical data are available particular with a head-to-head comparison design with standard topical emollient treatment. The aim of the present study was to evaluate the efficacy of topical urea (Ureadin Rx Db, ISDIN) containing also arginine and carnosine, in comparison with glycerol-based (15%) emollient topical product containing also vaseline (8%) (Dexeryl, Pierre Fabre ) in the treatment of xerotic skin in Type 2 diabetic patients.
The present study was a mono-centre prospective, parallel group, randomised, assessor-blinded trial. Randomisation list with a 1:1 ratio and with a block of 4 was generated by the mean of statistical software (G-Power). Study trial was registered in the Dutch Trials Register (trial number 3328). Local Institutional Review Board (Fitness Metabolic ONLUS Monterotondo) approved the study protocol. Study was performed between March 2011 and February 2012.
Patients were enrolled in the trial after their written informed consent according to the Declaration of Helsinki. Patients enrolled in this study were men and women, aged between 40 and 75 years, with a confirmed diagnosis of type 2 diabetes and moderate-to-severe foot xerosis, who had not used any topical moisturizers on their feet for at least 2 weeks. Insulin-dependent diabetes mellitus, presence of foot lesions and peripheral arterial diseases were the main exclusion criteria. We assessed the effect of urea 5% cream (UC) containing also arginine and carnosine on skin hydration in 40 type 2 diabetic patients treated with UC or the comparator (EC) for 28 days with a twice-daily application regimen. As comparator we have chosen a glycerol, vaseline and liquid paraffin cream (Dexeryl) which is commonly used as topical hydrating agent for the treatment of skin xerosis. Both treatments were applied on the feet (dorsal and plantar regions) and in the distal third of the leg.
The principal outcomes of the trial were the Dryness Area Severity Index (DASI) score, according to Serup et al., and the Visual Analogue Score (VAS) for skin dryness evaluated at baseline and at the end of study period by an investigator unaware of treatment allocation (GF). The DASI score evaluates dry skin using a 5-point Likert scale ranging from 0 (=no dryness) to 4 (=severe dryness). We used a visual analogue scales (VAS) for subjective evaluation of dryness of the skin; the results were converted to a points scale on which 0 denoted extreme skin dryness and 10 the best skin hydration state imaginable. Secondary endpoints of the study were the percentage reduction of DASI score in comparison with baseline values and the evolution of patient-assessed itch sensation according to Hagermark with a scale from 0 (extreme itch sensation) to 10 (not itch).
Statistical analyses were performed using SPSS statistical software (ver. 13.0). Data were expressed as mean (SD). All P values were two-sided. The present trial was designed as a superiority trial. The power calculation assumed a difference between the two treatments in the DASI score at week 4 of at least 1.1 points with an effect size of 0.6. This assumption provided 90% power at an alpha level of .05 (two-tailed test) for a sample size of at least 40 evaluable patients in total. Sample size calculation was performed using G*Power program Ver.3.03 (Kiel, Germany). Two-tailed unpaired T-test, two-tailed Mann–Whitney (unpaired) and Wilcoxon (paired) tests were applied to compare treatments and to compare baseline levels with values at the end of study period. The analysis was based on the intention-to- treat principle and involved all patients who were randomly assigned to the treatments. A P value ≤0.05 was considered statistically significant.
Patients characteristics at randomization, data presented as mean (SD)
UC group (n = 20)
EC group (n = 20)
History of Diabetes, years
Serum glucose mg/100 mL
VAS skin xerosis
Itching score (from 0 to 10)
Diabetes mellitus induces many pathophysiologic changes in the skin. Diabetes also induces increase in the dermis of advanced glycosylation end products (AGEs), which may be responsible for some skin changes in persons with elevated blood sugars. Xerosis (with prevalence higher than 40%) with pruritus and scleroderma-like skin changes are the most commonly observed cutaneous manifestations of this common disease. Xerosis of the diabetic foot could promote ulceration through the development of fissures and hyperkeratosis. Its treatment is therefore important and must be implemented early on. Skin xerosis is commonly treated with the repeated use of emollients and moisturizers. Their use is based on sound evidence of the importance of maintaining the skin's water content. Emollient products could vary in term of beneficial effects on the skin. Recent data have shown that topical urea can act not only as a simple hydrating molecule but in addition it could be able to improve cell differentiation of keratinocytes. In a randomized placebo controlled trial Garrigue et al. have shown that topical urea 5% is able to improve xerosis in the diabetic foot by 61% after 4 weeks of treatment. In our study we compared urea, arginine and carnosine topical product with a standard treatment reference (Dexeryl). Reduction of xerosis score observed in our trial was 90% in the UC group. This clinical effect could be due to the particular composition of UC. Urea and carnosine could favourably interfere with formation and accumulation of advanced glycated end-products. Topical urea is able to increase the synthesis of aquaporin in keratinocytes therefore increasing the hydration of the skin. Arginine supplementation improves microcirculation in diabetes. Therefore UC composition could have a strong rational as an “active” emollient for the treatment of skin xerosis observed in diabetic patients.
Our study has shown that application of urea 5% associated with arginine and carnosine cream increase skin hydration and alleviate the condition of skin dryness in Type 2 diabetic patients in comparison with a control glycerol-based emollient product. Some limitations should be considered in evaluating our results. First this study was not double-blind. The main difficulty in performing a double-blind trial in this setting was linked to the different formulations and texture of the study products. Therefore we decided to perform an assessor-blinded evaluation of the primary endpoint of the study. A second limitation of our study is that we have evaluated as primary endpoint a subjective clinical assessment parameters (DASI score and the VAS) instead of an instrumental objective variable. However the main therapeutic goal of emollient treatment in diabetes is to obtain an increase in hydration of the skin clinically evaluable. Further studies are necessary to evaluate if the treatment with this topical product could be associated with improvement in microcirculation and/or modification of skin structure in diabetes.
The study was funded by independent non profit source. Study drugs were supplied by Isdin Italy. No potential conflicts of interest relevant to this paper were reported.
- Gilgor RS, Lazarus GS: Skin manifestations of diabetes mellitus. In Diabetes Mellitus. Edited by: Rifkin H, Raskin P. RI Bray: Bowie; 1981:313–321.
- Goodfield MJD, Millard LG: The skin in diabetes mellitus. Diabetologia 1988, 31: 567–575. 10.1007/BF00264762PubMedView Article
- Pavicic T, Korting HC: Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. J Dtsch Dermatol Ges 2006,4(11):935–941. 10.1111/j.1610-0387.2006.06123.xPubMedView Article
- Khatib P, Oussama MN: Guidelines for the prevention, management and care of diabetes mellitus. EMRO Technical Publications Series 2006, 32: 1.
- Proksch E: The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008, 21: 75–80. 10.1159/000112957PubMedView Article
- Watkins P: The use of emollient therapy for ageing skin. Nurs Older People 2011, 23: 31–37.PubMedView Article
- Susanne G-B, Ingo F: Urea Uptake Enhances Barrier Function and Antimicrobial Defense in Humans by Regulating Epidermal Gene Expression. J Invest Dermatol 2012. 10.1038/jid.2012.42
- Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS: Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997, 129: 261–269. 10.1016/S0021-9150(96)06044-3PubMedView Article
- Frisbee JC, Stepp DW: Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 2001, 281: H1304-H1311.PubMed
- Beleznai T, Feher A: Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 2011,300(3):H777-H783. 10.1152/ajpheart.00831.2010PubMedPubMed CentralView Article
- Pfister F, Riedl E: Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol Biochem 2011,28(1):125–136. 10.1159/000331721PubMedView Article
- Méndez JD: Urea Inhibits the In vitro Formation of Fluorescent Advanced Glycation End Products. World Applied Sciences Journal 2007,2(2):090–098.
- World Medical Association Inc: Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009, 107: 403–405.
- Serup J: EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: clinical scoring systems. Skin Res Tech 1995, 1: 109–114. 10.1111/j.1600-0846.1995.tb00029.xView Article
- Hagermark O, Wahlgren CF: Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. J Dermatol Sci 1992, 4: 55–62. 10.1016/0923-1811(92)90059-KPubMedView Article
- Seirafi H, Farsinejad K, Firooz A, et al.: Biophysical characteristics of skin in diabetes: a controlled study. J Eur Acad Dermatol Venereol 2009, 23: 146–149. 10.1111/j.1468-3083.2008.02950.xPubMedView Article
- Lutgers HL, Graaff R, Links TP, et al.: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006, 29: 2654–2659. 10.2337/dc05-2173PubMedView Article
- Perez IM, Kohn SR: Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1994, 30: 201–213. 10.1016/S0190-9622(94)70017-6View Article
- Baalham P, Birch I, Young M, Beale C: Xerosis of the feet: a comparative study on the effectiveness of two moisturizers. Br J Community Nurs 2011,16(12):591–592. 594–7PubMedView Article
- Buraczewska I, Berne B: Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol 2007,156(3):492–498. 10.1111/j.1365-2133.2006.07685.xPubMedView Article
- Garrigue E, Martini J: Evaluation of the moisturizer Pèdimed in the foot care of diabetic patients. Diabetes Metab 2011, 37: 330–335. 10.1016/j.diabet.2010.12.004PubMedView Article
- Scheinfeld NS: Urea: a review of scientific and clinical data. Skinmed 2010, 8: 102–106.PubMed
- Gornik HL, Creager MA: Arginine and endothelial and vascular health. J Nutr 2004, 134: 2880S-2887S.PubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-5945/12/16/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.